The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP - PubMed (original) (raw)
Review
The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP
Carol A Colton et al. J Alzheimers Dis. 2008 Dec.
Abstract
Nitric oxide synthase 2 (NOS2) and its gene product, inducible NOS (iNOS) play an important role in neuroinflammation by generating nitric oxide (NO), a critical signaling and redox factor in the brain. Although NO is associated with tissue damage, it can also promote cell survival. We hypothesize that during long-term exposure to amyloid-beta (Abeta) in Alzheimer's disease (AD), NO levels fall in the brain to a threshold at which the protective effects of NO cannot be sustained, promoting Abeta mediated damage. Two new mouse models of AD have been developed that utilize this concept of NO's action. These mice express human amyloid-beta protein precursor (AbetaPP) mutations that generate Abeta peptides on a mouse NOS2 knockout background. The APP/NOS2(-/-) bigenic mice progress from Abeta production and amyloid deposition to hyperphosphorylated normal mouse tau at AD-associated epitopes, aggregation and redistribution of tau to somatodendritic regions of neurons and significant neuronal loss including loss of interneurons. This AD-like pathology is accompanied by robust behavioral changes. As APP/NOS2(-/-) bigenic mice more fully model the human AD disease pathology, they may serve as a tool to better understand disease progression in AD and the role of NO in altering chronic neurological disease processes.
Figures
Figure 1
Panel A: Average fold change (± SEM) in mRNA levels of pro-inflammatory (TNFα; NOS2) and repair [arginase 1 (AG1) and chitinase 3-like-1 (CH3L1)] cytokines from mixed cortical lysates from humans with AD (average age approximately 78 yrs; Stage 4–5 Braak scale). Quantitative RT-PCR data from AD samples were compared to brain samples from aged matched normal individuals. De-identified autopsied brain samples were provided by the Kathleen Bryan Brain Bank at Duke University Medical Center, Durham, NC as described [30]. Panel B: Average fold change (± SEM) in mRNA from aged (52–54 week old) APPSwDI/NOS2−/− mice compared to aged matched wild type (WT) mice. Pro-inflammatory genes were TNFα and IL-6 and repair genes were AG1 and YM1 (mouse homolog for CH3L1). All values are significantly greater than control with p ≤ 0.05 (Student’s t test) (for humans, n = 29 control; AD; mixed gender; for mice n = 5–6 mice, mixed gender).
Figure 2
Neuronal loss in APPSw/NOS2−/− compared to APPSw mice at 52–54 weeks of age. A,C,E = tyical views of hippocampus in APPSw mice. B,D,F = same areas in APPSw/NOS2−/− mice. Neurons were identified using NeuN immunochemistry. G: Unbaised stereology was used to count neurons in specific brain regions. A significant decrease (*** = p < 0.001) was observed in all regions in the APPSw/NOS2−/− (abbreviated AN2) mice compared to APPSw (abbreviated A), WT, NOS2−/− (abbreviated N2) mice. H: Summary of the percent changes in neuronal number.
Figure 3
Behavioral deficits in the APPsw/NOS2−/− compared to APPSw mice at 52–54 weeks age. The 2-day radial arm water maze was used to test learning and memory as described [136]. Data points represent the average (± SEM) number of errors in each of the 5 blocks of trials on day 2 of the testing paradym. *** p < 0.001 compared to either NOS2−/− or to APPSw, n = 7–14 mice/group.
Similar articles
- Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA. Wilcock DM, et al. J Neurosci. 2009 Jun 24;29(25):7957-65. doi: 10.1523/JNEUROSCI.1339-09.2009. J Neurosci. 2009. PMID: 19553436 Free PMC article. - Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2.
Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Gharkholonarehe N, Vitek MP, Colton CA. Wilcock DM, et al. J Neurosci. 2008 Feb 13;28(7):1537-45. doi: 10.1523/JNEUROSCI.5066-07.2008. J Neurosci. 2008. PMID: 18272675 Free PMC article. - Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ, Muñetón-Gómez V, Alvárez MI, Toledano-Díaz A. Merino JJ, et al. Curr Alzheimer Res. 2016;13(4):403-12. doi: 10.2174/1567205013666151116125714. Curr Alzheimer Res. 2016. PMID: 26567742 Review. - APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.
Crews L, Rockenstein E, Masliah E. Crews L, et al. Brain Struct Funct. 2010 Mar;214(2-3):111-26. doi: 10.1007/s00429-009-0232-6. Epub 2009 Nov 29. Brain Struct Funct. 2010. PMID: 20091183 Free PMC article. Review.
Cited by
- Effects of aged garlic extract and FruArg on gene expression and signaling pathways in lipopolysaccharide-activated microglial cells.
Song H, Lu Y, Qu Z, Mossine VV, Martin MB, Hou J, Cui J, Peculis BA, Mawhinney TP, Cheng J, Greenlief CM, Fritsche K, Schmidt FJ, Walter RB, Lubahn DB, Sun GY, Gu Z. Song H, et al. Sci Rep. 2016 Oct 13;6:35323. doi: 10.1038/srep35323. Sci Rep. 2016. PMID: 27734935 Free PMC article. - Elevated copper in the amyloid plaques and iron in the cortex are observed in mouse models of Alzheimer's disease that exhibit neurodegeneration.
Bourassa MW, Leskovjan AC, Tappero RV, Farquhar ER, Colton CA, Van Nostrand WE, Miller LM. Bourassa MW, et al. Biomed Spectrosc Imaging. 2013 Apr 1;2(2):129-139. doi: 10.3233/BSI-130041. Biomed Spectrosc Imaging. 2013. PMID: 24926425 Free PMC article. - Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies.
Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM. Shineman DW, et al. Alzheimers Res Ther. 2011 Sep 28;3(5):28. doi: 10.1186/alzrt90. Alzheimers Res Ther. 2011. PMID: 21943025 Free PMC article. - Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.
Kan MJ, Lee JE, Wilson JG, Everhart AL, Brown CM, Hoofnagle AN, Jansen M, Vitek MP, Gunn MD, Colton CA. Kan MJ, et al. J Neurosci. 2015 Apr 15;35(15):5969-82. doi: 10.1523/JNEUROSCI.4668-14.2015. J Neurosci. 2015. PMID: 25878270 Free PMC article.
References
- Akassoglou K. Nerve growth factor-independent neuronal survival: a role for NO donors. Mol Pharmacol. 2005;68:952–955. - PubMed
- Akiyama H. Inflammatory response in Alzheimer's disease. Tohoku J Exp Med. 1994;174:295–303. - PubMed
- Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1:1671–1679. - PubMed
- Albina JE. On the expression of nitric oxide synthase by human macrophages. Why no NO? J Leukoc Biol. 1995;58:643–649. - PubMed
- Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol. 2002;72:101–106. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG019740/AG/NIA NIH HHS/United States
- AG19780/AG/NIA NIH HHS/United States
- R01 AG019780/AG/NIA NIH HHS/United States
- AG030942/AG/NIA NIH HHS/United States
- R01 AG019780-05/AG/NIA NIH HHS/United States
- AG19740/AG/NIA NIH HHS/United States
- F32 AG030942/AG/NIA NIH HHS/United States
- P30 AG028377/AG/NIA NIH HHS/United States
- R01 AG019740-04/AG/NIA NIH HHS/United States
- F32 AG030942-02/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials